Pain Management Following Total Hip Arthroplasty Study

Clinical Trial Title

Programmed intermittent epidural bolus versus continuous epidural infusion for analgesia following total hip arthroplasty.

Clinical Trial Protocol Description:

Patients undergoing total hip arthroplasty will be randomized to one of two groups. Group 1 will consist of a standard post-operative epidural infusion of 0.1% bupivacaine, 5 mL/hr continuous infusion with 1 mL every 15 minutes as a bolus option. Group 2 will consist of a programmed intermittent epidural bolus of 5 mL every hour with 1 mL every 15 minutes as a bolus option. Both groups of patients will be allowed to have oral opioids and adjuvants following their surgery.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have total hip replacement surgery scheduled.
  • Are between the ages of 18 and 89.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a history of prior lumbar spine surgery.
  • Have a history of bleeding disorder or current use of anticoagulant/antiplatelet agents.
  • Have a history of opioid tolerance defined as the following:
    • At least 60 mg of oral morphine/daily
    • At least 25 mcg transdermal fentanyl/hour
    • At least 30 mg of oral oxycodone daily
    • At least 8 mg oral hydromorphone daily
    • At least 25 mg oral oxymorphone daily
    • An equianalgesic dose of another opioid daily for a week or longer
  • Are allergic to or have a documented reaction to bupivacaine or amide local anesthetics.
  • Have a disability or impairment such that using a patient-controlled bolus would not be possible.
  • Have surgeon-specified perioperative procedures that precludes the current study’s protocol.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Adam C. Young, MD

Contact Information

Sherry Robison, MBA

(312) 942-2985